Moderna (MRNA) Soars More Than 140% in a Single Day on Cancer Vaccine Trial Success

Moderna Posts Its Best Trading Day Ever: +143.79% in a Single Session

Moderna (MRNA) closed Wednesday, August 19, 2026 at $153.49, up +143.79% (+$90.53) from the prior close of $62.96, after opening the session at $116.02 and touching an intraday high of $163.47 — its highest level since 2024 — before easing slightly into the close. It's by far the best single trading session in the company's history, driven by the success of its personalized cancer vaccine developed with Merck and, on the same day, by FDA approval of its new flu vaccine. This article breaks down the clinical trial data, the market's reaction, and what to watch now that the stock is trading at two-year highs.

Context: What Happened

Two pieces of news landed the same day to send the stock soaring. The first and biggest: Moderna and Merck announced that their personalized mRNA cancer therapy — the individualized neoantigen therapy intismeran (mRNA-4157), combined with Merck's Keytruda — successfully met its primary and secondary endpoints in a Phase 3 trial for high-risk melanoma patients. It's the first-ever positive Phase 3 result for an individualized neoantigen therapy and for an mRNA-based cancer treatment. The second: the FDA approved mFLUSIVA that same day, Moderna's new flu vaccine for adults 50 and older, its fifth global product and fourth FDA-approved therapy.

The Clinical Trial That Changed Everything

The Phase 3 INTerpath-001 trial enrolled 1,137 patients with surgically removed stage IIB-IV melanoma. The intismeran-Keytruda combination met both the recurrence-free survival goal and the distant metastasis-free survival goal, though the exact magnitude of the benefit hasn't been disclosed in the initial announcements. For reference, the earlier Phase 2b study (157 patients) had already shown a 49% reduction in recurrence-or-death risk and a 59% reduction in distant-metastasis-or-death risk at 60.3 months of follow-up. Analysts consulted by Reuters described the data as a major validation for mRNA-based therapies beyond infectious-disease vaccines, though some experts cautioned they're still awaiting the full trial results to confirm the magnitude of the benefit.

Market Reaction: The Strongest Session in Company History

The move kept accelerating throughout the session. In premarket trading, the stock rose as much as 57.29% to $99.02. Right at the open, the gain already exceeded 88-94%, and by mid-morning the stock was trading up 126.5%, at $142.61 — a level that had already surpassed the highest price target across the entire analyst consensus, Piper Sandler's $77 (28.6% above it), against a consensus average of just $48.92 and a pre-announcement rating split of mostly "hold" (1 buy, 12 hold, 2 sell). By the close, the stock had touched an intraday high of $163.47 before easing to a final $153.49, on volume far above normal. The move added roughly $30 billion to the company's market capitalization, which is now up 357% year-to-date in 2026.

Traceability note: Alpha Vantage's quote data (GLOBAL_QUOTE) was still reflecting the August 18 close ($62.96) at the time this article was written, not yet having incorporated the August 19 session — common on days with extreme moves, given the provider's update lag. The August 19 intraday and closing figures come from verified market-data sources (stockanalysis.com, Yahoo Finance, Reuters and Investing.com), all of which agree on the same prior close of $62.96, which serves as the common anchor point between the API and press coverage.

The Ripple Effect on Merck and the Sector

The rally wasn't limited to Moderna. Merck (MRK) — whose Keytruda is the other half of the combination therapy — opened the session up 8.82%, a move analysts also tie to relief over Keytruda's looming patent expiration in the coming years: a new oncology revenue stream helps offset that future pressure. Alpha Vantage's news-sentiment data on MRNA shows a predominantly bullish read across the coverage focused on the clinical trial, with MRK appearing as a related ticker at 70-100% relevance in several of those pieces.

Levels and Figures to Watch

With the stock now trading at two-year highs, several numbers frame the field for coming sessions: today's intraday high of $163.47 stands as the first resistance reference; the fact that the price already blew past the highest target in the entire analyst consensus points to a round of upward target revisions in the coming days, which will be key to gauging whether the market sees the new valuation as sustainable; and the sheer size of the move itself — a single-session re-rating of more than 140% on a company worth tens of billions of dollars — makes elevated volatility in the immediate sessions likely, typical of this kind of binary event in biotech.

Implications for Investors

For biotech investors, Moderna's case illustrates the classic pattern of binary risk tied to clinical trial readouts: a single Phase 3 data readout added more market capitalization in a day than the entire company was worth just 24 hours earlier. The milestone also carries a deeper strategic significance: it confirms, for the first time, that Moderna's mRNA platform works beyond infectious-disease vaccines, at a moment when the company needed to prove exactly that following the decline in COVID-19 vaccine revenue. It's worth remembering, though, that the analysts cited by Reuters are urging caution until the full trial data is available, and that the earlier Phase 2b results — while strong — don't by themselves guarantee final regulatory approval or a successful commercial launch. The stock's 357% year-to-date gain also puts Moderna in demanding valuation territory, where any news that shifts expectations — positive or negative — can trigger moves of an unusual magnitude.

Conclusion

Moderna posted the best trading session in its history on August 19, 2026, surging 143.79% to $153.49, after its personalized cancer vaccine combined with Merck's Keytruda succeeded in a Phase 3 melanoma trial, and the FDA approved its new flu vaccine the same day. The move, which touched an intraday high of $163.47 and added roughly $30 billion in market cap, had already surpassed the highest target in the entire analyst consensus by premarket trading, and also dragged Merck along, which opened up 8.82%. With the stock at two-year highs and up 357% year-to-date, investor attention now shifts to the full trial data and to how the analyst consensus revises its price targets after a move of this size.